Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
8.6 CAD | -0.58% | -0.35% | -6.72% |
Apr. 22 | BioSyent Inc.(TSXV:RX) dropped from S&P/TSX Venture Composite Index | CI |
Apr. 01 | BioSyent To Present At LD Micro New York Investor Conference | MT |
Sales 2024 * | 35M 25.62M | Sales 2025 * | 38.7M 28.33M | Capitalization | 100M 73.49M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 2.87 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.59 x |
P/E ratio 2024 * |
18.4
x | P/E ratio 2025 * |
15.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 60.46% |
Latest transcript on BioSyent Inc.
1 day | -0.58% | ||
1 week | -0.35% | ||
1 month | -0.58% | ||
3 months | -1.71% | ||
6 months | +7.50% | ||
Current year | -6.72% |
Managers | Title | Age | Since |
---|---|---|---|
René C. Goehrum
CEO | Chief Executive Officer | 64 | 95-12-31 |
Robert March
DFI | Director of Finance/CFO | - | 18-09-09 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 14-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sara Elford
BRD | Director/Board Member | 53 | 18-01-07 |
René C. Goehrum
CEO | Chief Executive Officer | 64 | 95-12-31 |
Peter Lockhard
BRD | Director/Board Member | 60 | 02-05-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-06 | 8.6 | -0.58% | 2 232 |
24-05-03 | 8.65 | -0.46% | 9,142 |
24-05-02 | 8.69 | 0.00% | 3,000 |
24-05-01 | 8.69 | +1.05% | 400 |
24-04-30 | 8.6 | -0.35% | 504 |
Delayed Quote Toronto S.E., May 06, 2024 at 11:27 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.72% | 73.36M | |
+30.79% | 662B | |
+21.96% | 546B | |
-5.28% | 359B | |
+16.87% | 323B | |
+4.72% | 289B | |
+13.68% | 234B | |
+3.81% | 198B | |
-10.63% | 194B | |
+4.00% | 167B |
- Stock Market
- Equities
- RX Stock